In a nutshell
This study examined whether there is an increased risk of hypertension among cancer patients being treated with regorafenib (Stivarga).
Some background
Vascular endothelial growth factor receptors (VEGF-r) are complexes on the surface of cells which stimulate the growth of new blood vessels, and are crucial for cancer growth and spread. Regorafenib (Stivarga) is a VEGF-r inhibitor, and has been shown to increase survival rates among advanced colorectal cancer patients. However, regorafenib has also been shown to be associated with severe side effects, including liver damage, diarrhea and fatigue. Hypertension (high blood pressure) has also been observed in many patients receiving regorafenib and other VEGF-r inhibitors, such as bevacizumab (Avastin). The current review assessed all recently published data regarding the association between regorafenib treatment and hypertension.
Methods & findings
Five clinical trials, including a total of 1,069 cancer patients, were reviewed in this analysis. Overall, 44.4% of patients taking regorafenib developed hypertension. The incidence, however, varied widely depending on the type of cancer being treated. Among metastatic (wide spread) colorectal cancer patients, 27.8% of patients receiving regorafenib were found to develop hypertension.
The bottom line
This review concluded that regorafenib is associated with a significant increase in the risk of developing hypertension.
The fine print
The trials reviewed in this analysis included many types of cancer patients, and only a small number of colorectal cancer patients were included. Furthermore, most trials did not account for hypertension risk factors among patients, which may have influenced results.
What’s next?
Consult with your physician regarding the prevention of possible adverse effects if you are receiving or considering treatment with regorafenib.
Published By :
European journal of clinical pharmacology
Date :
Oct 23, 2013
